Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics announced it will present data on the manufacturing process for BEAM-101 at the 2024 European Hematology Association (EHA) Hybrid Congress. The presentation will highlight the closed and automated manufacturing process developed for the BEACON Phase 1/2 clinical trial. This data is important for advancing treatments for patients with sickle cell disease. The poster presentation, titled 'Robust autologous CD34+ HSPC manufacturing with a closed and automated process optimized for patients with sickle cell disease,' will be delivered by Paul Kopesky, Ph.D., on June 14, 2024, at 6:00 p.m. CEST in Madrid, Spain.
Beam Therapeutics Inc. will have its CEO, John Evans, participate in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference on May 15, 2024. This event will be live webcasted and archived on the company's website.
Beam Therapeutics reported progress across its high-priority programs, including completing dosing for the BEACON Phase 1/2 Trial of BEAM-101 in sickle cell disease and initiating a trial for BEAM-302 in alpha-1 antitrypsin deficiency. The company ended the first quarter of 2024 with $1.1 billion in cash and expects to support its operating plans into 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.